当前,流感季正持续“冲顶”,感染人群基数扩大带动用药需求激增。与往年不同的是,今年的抗流感战场已不再是进口药与经典老药的天下。随着多款国产创新药今年密集上市,以“一次服药,全程起效”为卖点的新一代流感药竞赛悄然开启。 多款新药上市让患者的选择更为从容。然而,从不到2元一粒的奥司他韦集采仿制药,到售价超200元的原研创新流感药,面对百亿元规模的流感药市场与日趋同质化的研发赛道,国产药企能否凭借创新...
Source Link当前,流感季正持续“冲顶”,感染人群基数扩大带动用药需求激增。与往年不同的是,今年的抗流感战场已不再是进口药与经典老药的天下。随着多款国产创新药今年密集上市,以“一次服药,全程起效”为卖点的新一代流感药竞赛悄然开启。 多款新药上市让患者的选择更为从容。然而,从不到2元一粒的奥司他韦集采仿制药,到售价超200元的原研创新流感药,面对百亿元规模的流感药市场与日趋同质化的研发赛道,国产药企能否凭借创新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.